C12N 2710/16061
Methods of inactivation or attenuation
C12N2710/16061 (Methods of inactivation or attenuation) appears on 30 US grants and 36 published applications in this corpus.
Search patents in C12N- Granted patents
- 30
- Published applications
- 36
- Assignees
- 31
- Inventors
- 65
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 2 |
| 2004 | 0 | 4 |
| 2005 | 2 | 3 |
| 2006 | 3 | 1 |
| 2007 | 1 | 1 |
| 2008 | 1 | 3 |
| 2009 | 3 | 3 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 1 | 3 |
| 2013 | 0 | 1 |
| 2014 | 1 | 2 |
| 2015 | 3 | 0 |
| 2016 | 1 | 2 |
| 2017 | 0 | 2 |
| 2018 | 1 | 1 |
| 2019 | 1 | 2 |
| 2020 | 1 | 0 |
| 2021 | 1 | 1 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
| 2026 | 2 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions and methods for the treatment of skin diseases16 Jun 2026US 12,655,447 B2Krystal Biotech, Inc.
- Vaccines for treating SARS infections in cancer patients6 Jan 2026US 12,516,296 B2City of Hope
- EHV with inactivated UL18 and/or UL812 Jul 2022US 11,384,365 B2
- Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors19 Oct 2021US 11,149,255 B2BioVentures, LLC
- Alkaloids and their preparation and application as anti-HSV-1 agents5 May 2020US 10,639,303 B2Ocean University of China
- Modified Herpes Simplex Virus Type 16 Nov 2025US 2025/0340903 A1Eg 427
- Replication-defective vaccines and uses thereof7 Dec 2023US 2023/0390386 A1Rutgers, The State University of New Jersey
- Vaccines for treating sars infections in cancer patients27 Oct 2022US 2022/0340884 A1City of Hope
- Compositions and methods for the treatment of skin diseases23 Dec 2021US 2021/0395775 A1Krystal Biotech, Inc.
- Ehv with inactivated ul18 and/or ul819 Sep 2019US 2019/0284577 A1Boehringer Ingelheim Vetmedica GmbH
Most cited
By later US patents
- Preservation of blood, tissues and biological fluids22US 5,609,864 A1997
- Preservation of blood, tissues and biological fluids16US 5,360,605 A1994
- Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA9US 6,887,707 B2University of Washington · 2005
- Arginine inactivation of viruses9US 8,980,610 B2Biogen Idec MA Inc. · 2015
- Recombinant infectious laryngotracheitis virus and uses thereof7US 6,875,856 B2Syntro Corporation · 2005